HK Stock Market Move | PA GOODDOCTOR (01833) rose by more than 9%, the company continues to benefit from the deep synergy of the group under the empowerment of AI, and its operational capabilities continue to be optimized.

PA GOODDOCTOR (01833) rose by over 9%, reaching an increase of 8.97% at the time of publication, with a price of 7.17 Hong Kong dollars and a trading volume of 49.3474 million Hong Kong dollars. On the news front, recently, Roche Pharmaceuticals China team visited the headquarters of PA GOODDOCTOR, and the two sides conducted in-depth discussions on business insurance innovation, comprehensive cancer management, chronic disease services, and internet healthcare, clarifying the direction and implementation plan of multi-dimensional cooperation, jointly exploring a new integrated model of "medicine + insurance + health services". In addition, PA GOODDOCTOR's AI doctor service - Ping An ZhiXiang family doctor, has been fully integrated into Ping An's entire ecosystem apps such as Ping An Jin Guanjia and Ping An Hao Chezhu, reaching a serviceable population of 90 million monthly active users. Users can directly access Ping An ZhiXiang family doctor through various Ping An ecosystem portals such as insurance, banking, securities, and car owners. In the first quarter of this year, PA GOODDOCTOR achieved a total revenue of 1.159 billion RMB, a year-on-year growth of 9.1%, and adjusted net profit of 84.4 million RMB, a year-on-year increase of 45.8%. At the end of the reporting period, the company had provided services to over 7,500 paid corporate clients in the past 12 months, an increase of nearly 89% year-on-year. In addition, the number of users using AI doctors continues to grow, exceeding 5.6 million. CICC previously pointed out that considering the company's continuous benefits from group synergy empowerment and continuous optimization of operating capabilities under AI empowerment, it initiated coverage of PA GOODDOCTOR with an outperform industry rating and a target price of 14.20 Hong Kong dollars.